GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » EBITDA Margin %

Everest Medicines (HKSE:01952) EBITDA Margin % : -314.55% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Everest Medicines's EBITDA for the six months ended in Dec. 2023 was HK$-402.7 Mil. Everest Medicines's Revenue for the six months ended in Dec. 2023 was HK$128.0 Mil. Therefore, Everest Medicines's EBITDA margin for the quarter that ended in Dec. 2023 was -314.55%.


Everest Medicines EBITDA Margin % Historical Data

The historical data trend for Everest Medicines's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines EBITDA Margin % Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - - -1,804,751.52 -1,554.97 -591.29

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,148,875.76 -61,692.40 3,790.27 -4,232.68 -314.55

Competitive Comparison of Everest Medicines's EBITDA Margin %

For the Biotechnology subindustry, Everest Medicines's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Medicines's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Everest Medicines's EBITDA Margin % falls into.



Everest Medicines EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Everest Medicines's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-814.458/137.742
=-591.29 %

Everest Medicines's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-402.662/128.013
=-314.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Everest Medicines  (HKSE:01952) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Everest Medicines EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Everest Medicines's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Everest Medicines (HKSE:01952) Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Everest Medicines (HKSE:01952) Headlines

No Headlines